semaglutide news today 2025 Novo Nordisk has announced that the FDA has approved the Wegovy® pill (once-daily oral 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults New in the August 14,

Some community members report subjective improvements in energy and well-being during or shortly after a course

Retatrutide is not currently approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for routine clinical use in the UK

Some research also suggests it may play a supportive role in: Liver health, Heart function, Metabolic conditions such as PCOS, Fatigue related to obesity

We also discuss how these actions influence intestinal and extraintestinal diseases and emerging therapeutic strategies using SCFAs

e , NCI-H716 cells were treated with GPCR antagonists (10 M) or vehicle (DMSO) for 15 min before P9 treatment (50 g ml 1 ), then incubated for an additional 2 h, after which GLP-1 secretion was analyzed (n = 6 per group)